{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:27:25Z","timestamp":1792020445437,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.kint.2018.11.044","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T01:26:42Z","timestamp":1552094802000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"96","author":[{"given":"Ron T.","family":"Gansevoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maatje D.A.","family":"van Gastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime D.","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Stade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.11.044_bib1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.044_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.11.044_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and european renal best practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.044_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2018.11.044_bib6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.2013101037","article-title":"Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: From bench to bedside and back again","volume":"25","author":"Rinschen","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev Genet"},{"key":"10.1016\/j.kint.2018.11.044_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2018.11.044_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2018.11.044_bib10","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: Optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.044_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib13","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.11.044_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.08.007","article-title":"Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease","volume":"49","author":"Lacquaniti","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.kint.2018.11.044_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.044_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.044_bib17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1515\/cclm-2014-0379","article-title":"Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology","volume":"52","author":"Bolignano","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.kint.2018.11.044_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrendo.2015.224","article-title":"Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis","volume":"12","author":"Christ-Crain","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.kint.2018.11.044_bib19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1210\/jc.2010-2499","article-title":"Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states","volume":"96","author":"Balanescu","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2018.11.044_bib20","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1515\/cclm-2016-0559","article-title":"Comparison of ex\u00a0vivo stability of copeptin and vasopressin","volume":"55","author":"Heida","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.kint.2018.11.044_bib21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2014030260","article-title":"Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study","volume":"26","author":"Ponte","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib22","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","article-title":"Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease","volume":"99","author":"Roussel","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2018.11.044_bib23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2215\/CJN.08690813","article-title":"Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients","volume":"9","author":"Zittema","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib24","doi-asserted-by":"crossref","unstructured":"Ettema EM, Heida JE, Casteleijn NF, et\u00a0al. The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels. KI Reports. 2017;2:410\u2013419.","DOI":"10.1016\/j.ekir.2017.01.006"},{"key":"10.1016\/j.kint.2018.11.044_bib25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.044_bib26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1681\/ASN.V491654","article-title":"The spectrum of autosomal dominant polycystic kidney disease in children","volume":"4","author":"Fick","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.11.044_bib28","first-page":"629","article-title":"Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease","volume":"53","author":"Seeman","year":"2004","journal-title":"Physiol Res"},{"key":"10.1016\/j.kint.2018.11.044_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000326902","article-title":"Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease","volume":"34","author":"Meijer","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2018.11.044_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Biological variability of estimated GFR and albuminuria in CKD","volume":"2","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.044_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: a novel target for the prevention and retardation of kidney disease?","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000382081","article-title":"Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?","volume":"41","author":"Casteleijn","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2018.11.044_bib36","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"112\u2013119","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.kint.2018.11.044_bib37","first-page":"R1095","article-title":"Effects of dietary protein intake on vasoactive hormones","volume":"258","author":"Daniels","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2018.11.044_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.06.017","article-title":"Estimation of total kidney volume in autosomal dominant polycystic kidney disease","volume":"66","author":"Spithoven","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.044_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2018.11.044_bib40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.11.044_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/CS20080140","article-title":"Gender and renal function influence plasma levels of copeptin in healthy individuals","author":"Bhandari","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kint.2018.11.044_bib42","first-page":"34A","article-title":"Copeptin, a surrogate for vasopressin, predicts disease progression and tolvaptan treatment efficacy in ADPKD. results of the TEMPO 3:4 trial","volume":"27","author":"Gansevoort","year":"2016","journal-title":"ASN Kidney Week J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819300419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819300419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:52:52Z","timestamp":1758761572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819300419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0085253819300419"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.044","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}